Article
Epstein-Barr virus strain heterogeneity impairs human T-cell immunity.
Cancer immunology, immunotherapy : CII - 1 Apr 2018
Cirac Ana, Stützle Simon, Dieckmeyer Michael, Adhikary Dinesh, Moosmann Andreas, Körber Nina, Bauer Tanja, Witter Klaus, Delecluse Henri-Jacques, Behrends Uta, Mautner Josef
Abstract excerpt
The Epstein-Barr virus (EBV) establishes lifelong infections in > 90% of the human population. Although contained as asymptomatic infection by the immune system in most individuals, EBV is associated with the pathogenesis of approximately 1.5% of all cancers in humans. Some of these EBV-associated tumors have been successfully treated by the infusion of virus-specific T-cell lines. Recent sequence analyses of a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
